APO-RABEPRAZOLE 20 MG — DIN 02345587
RABEPRAZOLE SODIUM : 20 MG · APOTEX INC · TABLET (ENTERIC-COATED) · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is APO-RABEPRAZOLE?
APO-RABEPRAZOLE 20 MG contains RABEPRAZOLE SODIUM : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02345587, held by APOTEX INC, supplied as TABLET (ENTERIC-COATED) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Apr-2025. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is APO-RABEPRAZOLE used for?
APO-RABEPRAZOLE (rabeprazole sodium) is indicated for treatment of conditions where a reduction of gastric acid secretion is required, such as: symptomatic relief and healing of erosive or ulcerative gastroesophageal reflux disease (GERD); long-term maintenance of healing of erosive or ulcerative gastroesophageal reflux disease (GERD); treatment of symptoms (i.e., heartburn and regurgitation) in symptomatic gastroesophageal reflux disease (GERD), also called non-erosive reflux disease (NERD); symptomatic relief and healing of duodenal ulcers; symptomatic relief and healing of gastric ulcers; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome; eradication of Helicobacter pylori (H. pylori) associated with duodenal ulcer disease (active or history within the past 5 years). Rabeprazole, in combination with appropriate antibacterial therapeutic regimens such as amoxicillin and clarithromycin, is indicated for the treatment of patients with duodenal ulcer disease associated with H. pylori infection. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Rabeprazole cost around the world?
Rabeprazole is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 8 | 59 | AUD███.██ |
| Greece | producer price (ex-factory) | 6 | 6 | EUR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| South Africa | single exit price | 1 | 2 | ZAR███.██ |
69 pack listings across 17 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Rabeprazole pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Rabeprazole in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
18 holders have a Canadian DIN containing Rabeprazole, across 38 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JANSSEN INC | 2 | 2 | PARIET, ENTERIC-COATED TABLET 10MG, PARIET, ENTERIC-COATED TABLET 20MG | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 2 | SANDOZ RABEPRAZOLE | Sourceable in Canada |
| SANIS HEALTH INC | 2 | 2 | RABEPRAZOLE EC | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 2 | 2 | RABEPRAZOLE | Sourceable in Canada |
| SUN PHARMA CANADA INC | 4 | 0 | TARO-RABEPRAZOLE, TARO-RABEPRAZOLE EC | No marketed DIN |
| LABORATOIRE RIVA INC. | 2 | 0 | RIVA-RABEPRAZOLE EC | No marketed DIN |
| MELIAPHARM INC | 2 | 0 | RABEPRAZOLE EC | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MYLAN-RABEPRAZOLE | No marketed DIN |
| NT PHARMA CANADA LTD | 2 | 0 | NTP-RABEPRAZOLE EC | No marketed DIN |
| PATRIOT A DIVISION OF JANSSEN INC | 2 | 0 | PAT-RABEPRAZOLE | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-RABEPRAZOLE EC | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | PRO-RABEPRAZOLE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | TABLET (ENTERIC-COATED) |
| Route | ORAL |
| Pack configuration (monograph) | HDPE bottles of 100 and unit dose packages of 30 and 100 tablets |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Rabeprazole |
|---|---|
| ATC code | A02BC04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02345587 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2345587 |
| Brand name | APO-RABEPRAZOLE |
| Generic / active ingredient | RABEPRAZOLE SODIUM : 20 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | A02BC04 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02BC |
| Current status | CANCELLED POST MARKET |
| Status date | 17-Apr-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 38 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PARIET, ENTERIC-COATED TABLET 10MG | 10 MG | TABLET (ENTERIC-COATED) | JANSSEN INC | MARKETED | 02243796 |
| PARIET, ENTERIC-COATED TABLET 20MG | 20 MG | TABLET (ENTERIC-COATED) | JANSSEN INC | MARKETED | 02243797 |
| RABEPRAZOLE | 20 MG | TABLET (ENTERIC-COATED) | SIVEM PHARMACEUTICALS ULC | MARKETED | 02385457 |
| RABEPRAZOLE | 10 MG | TABLET (ENTERIC-COATED) | SIVEM PHARMACEUTICALS ULC | MARKETED | 02385449 |
| RABEPRAZOLE EC | 20 MG | TABLET (ENTERIC-COATED) | SANIS HEALTH INC | MARKETED | 02356538 |
| RABEPRAZOLE EC | 10 MG | TABLET (ENTERIC-COATED) | SANIS HEALTH INC | MARKETED | 02356511 |
| SANDOZ RABEPRAZOLE | 20 MG | TABLET (ENTERIC-COATED) | SANDOZ CANADA INCORPORATED | MARKETED | 02314185 |
| SANDOZ RABEPRAZOLE | 10 MG | TABLET (ENTERIC-COATED) | SANDOZ CANADA INCORPORATED | MARKETED | 02314177 |
| ABBOTT-RABEPRAZOLE | 10 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | 02422638 |
| ABBOTT-RABEPRAZOLE | 20 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | CANCELLED POST MARKET | 02422646 |
2 · Same class — other molecules in ATC A02BC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pantoprazole | ABBOTT-PANTOPRAZOLE · ACT PANTOPRAZOLE · AG-PANTOPRAZOLE · AG-PANTOPRAZOLE SODIUM · +37 more | 98 | 39 | Yes |
| Esomeprazole | APO-ESOMEPRAZOLE · APO-ESOMEPRAZOLE DELAYED-RELEASE · ESOMEPRAZOLE · ESOMEPRAZOLE DR · +14 more | 46 | 26 | Yes |
| Lansoprazole | APO-LANSOPRAZOLE · AVA-LANSOPRAZOLE · DOM-LANSOPRAZOLE · LANSOPRAZOLE · +15 more | 41 | 19 | Yes |
| Omeprazole | ACH-OMEPRAZOLE · AG-OMEPRAZOLE DR · AHI-OMEPRAZOLE · APO-OMEPRAZOLE · +31 more | 57 | 12 | Yes |
| Rabeprazole | ABBOTT-RABEPRAZOLE · AG-RABEPRAZOLE · APO-RABEPRAZOLE · DOM-RABEPRAZOLE EC · +15 more | 38 | 8 | Yes |
| Dexlansoprazole | APO-DEXLANSOPRAZOLE · DEXILANT · DEXLANSOPRAZOLE | 8 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02BA | Cimetidine · Famotidine · Famotidine, Combinations · Nizatidine · Ranitidine · +1 more | 235 | 26 |
| A02BX | Alginic Acid · Pirenzepine · Sucralfate | 32 | 4 |
| A02BB | Misoprostol | 10 | 2 |
| A02BD | Bismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-RABEPRAZOLE called?
The same molecule, Rabeprazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Parbezol | Latin | Australia |
| Rabeprazole Sandoz | Latin | Australia |
| RABEPRAZOLE-WGR | Latin | Australia |
| Rabeprazole Mylan | Latin | Australia |
| Rabeprazole SUN | Latin | Australia |
| Zabep | Latin | Australia |
| Pariet | Latin | South Africa |
| Rabeprazole Viatris | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.